Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Clas Ohlson’s sales increased in December

Sales in December increased by 9 per cent to 1,204 MSEK (1,108). Organic sales increased by 6 per cent compared to the previous year. Sales in comparable units and local currency increased by 6 per cent compared to the previous year. Online sales increased by 26 per cent to 136 MSEK (108). Compared to the same month last year the store network increased by 1 store. At the end of the period, the total number of stores was 230 (229).Distribution of sales Month Accumulated December Change May-December ChangeMSEK

Pexip adds USD 6.6 million in Annual Recurring Revenue during Q4 2021

(Oslo, Norway, January 10, 2022) In this trading update, Pexip Holding ASA (“Pexip” or “The Company” Oslo Børs Ticker: PEXIP) presents its Annual Recurring Revenue (ARR) for the fourth quarter (Q4) of 2021. In Q4 2021, Pexip increased its ARR with 30% year-on-year to USD 106.4 million.· Pexip’s subscription base measured in ARR reached USD 106.4 million in Q4 2021, up from USD 81.9 million in Q4 2020, representing a year-on-year increase of 30% or USD 24.6 million for 2021 full year. · Of the 30% year-on-year growth in ARR, 29 percentage points (pp) are from new customers. Net revenue

DSRT: Desert Control appoints Michael Davidson as CEO of Desert Control Americas to spearhead the company’s market entry and growth in the United States.

ISSUER DESERT CONTROL AS Stavanger, Norway/Palo Alto, California, USA, 10 January 2022.Michael Davidson, Ph.D., joins Desert Control as CEO of Desert Control AmericasInc.Desert Control was founded in Norway to specialize in climate-smart Agri-techsolutions to combat desertification, soil degradation, and water scarcity. Itspatented Liquid Natural Clay (LNC) enables sustainable ecosystem management byrestoring and protecting soil’s ability to preserve water and increase yieldsfor agriculture, forests, and green landscapes.In December 2021, Desert Control Americas was

Swedavia’s traffic statistics for December and the full-year 2021

In December, nearly 1.6 million passengers flew via Swedavia’s ten airports, a decrease of 44 per cent compared to 2019. For the full-year 2021, the total number of passengers was nearly 12 million, a decrease of more than 70 per cent compared to passenger volume in 2019, before the Covid-19 pandemic struck. As a result, 2021 was the second straight year that air travel was heavily impacted by the Covid pandemic. Despite the rebound during the autumn, air travel remained at levels comparable to those seen in the early 1980s. Since the start of the pandemic, air travel at Swedavia’s airports

Saga Pure ASA – Grant of share options – Amendments to previously granted share options

In the extraordinary general meeting held on 19 February 2021, the Board of Directors of Saga Pure ASA (the "Company") was given an authorization to grant share options to employees and key persons in the Company for up to 20 million shares. Pursuant to such authorization, the Board of Directors have now granted 3,000,000 share options to an employee. The share options vest and may be exercised over a period of two years, calculated from 1 January 2022. 1,500,000 share options will vest in 6 months, and such share options hold a strike price of NOK 4.00. 750,000 share options vest on the

Hansa Biopharma provides business update including certain key financials

· Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in Central Eastern Europe and Israel  · First patients enrolled into the pivotal U.S. ConfIdeS study; Agreement established with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease · Platform strategy: Hansa to explore desensitization treatment in allogeneic hematopoietic stem cell transplantation   · Year-end cash position of SEK 889 million; Hansa financed into 2023, as previously guidedLund,

Nordea Bank Abp: Repurchase of own shares on 07.01.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares07.01.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 07.01.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XSTO 341,215 10.97 3,743,660.38XHEL 259,813 10.95 2,844,380.76CEUX 324,622 10.96 3,558,213.08AQEU 38,812 10.96

Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Oslo, Norway, 7 January 2022 Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin[® ]([177]Lu lilotomab satetraxetan) in 3[rd]-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL). The Company reports that 106 patients have been enrolled into PARADIGME as of 6 January 2022. Given the ongoing impact from the SARS-CoV-2 omicron variant on patient recruitment, the Company now anticipates the preliminary three-month data readout from PARADIGME to be reported during the second half of

Storytel completes acquisition of streaming service Audiobooks.com

The Storytel Group (“Storytel”), one of the world’s largest audiobook and e-book streaming companies, has completed the acquisition of Audiobooks.com from KKR as was announced on November 12, 2021. Audiobooks.com will be consolidated into Storytel’s financials as of January 7, 2022.The transaction details are confirmed as previously announced with a purchase price, paid in cash, calculated based on an enterprise value of USD 135 million on a cash and debt free basis. The acquisition is financed through existing funds and a newly issued SEK 500 million bridge loan facility, with termination

Exercise of the over-allotment option in the IPO of Devyser Diagnostics AB (publ)’s shares and end of the stabilisation period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASEStockholm, 7 January, 2022 Carnegie Investment Bank AB (publ) (“Carnegie”) exercises the over-allotment option regarding 610,886 shares in Devyser Diagnostics AB (publ) (“Devyser” or the “Company”). The stabilisation period has now ended and no further

BerGenBio - Mandatory notification of trade by Primary Insiders

Bergen, Norway, 7 January 2022 – BerGenBio ASA (OSE: BGBIO) (the “Company”), has been notified that Martin Olin, CEO and primary insider of BerGenBio ASA, has bought 10,000 shares in BerGenBio ASA at an average price of NOK 20.43 per share. After the transaction Mr. Olin holds 28,000 shares in BerGenBio ASA.   Please see the attached document for further details of the transaction. Contact:  ir@bergenbio.com Rune Skeie, CFO, BerGenBio ASA rune.skeie@bergenbio.com   This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (

#22-8 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Aiforia: End of the stabilization period; exercise of over-allotment option and cancellation of treasury shares

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.With reference to the prospectus of Aiforia Technologies Plc ("Aiforia") dated 26 November 2021 and the company release dated 9 December 2021 regarding the results of the initial public offering of Aiforia (the "Offering"), Aiforia has received notification that Swedbank AB (publ) acting as the stabilizing manager (

#22-7 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 07.01.2022

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 07.01.2022 at 18:30 EET ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 07.01.2022 Date 07.01.2022Exchange transaction BuyShare class ALEXAmount 431Average price/share 8.8900 EURHighest price/share 8.8900 EURLowest price/share 8.8900 EURTotal price 3,831.59 EUR The shares held by Alexandria Pankkiiriliike Oyj on 07.01.2022: ALEX 47,118 On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

Concentric closes its facility in Chivilcoy, Argentina

Concentric today announces the company has decided to close its facility in Chivilcoy, Argentina. Concentric has carefully evaluated different alternatives for the facility in Argentina and has concluded that regrettably it is not viable to continue the operations because of the sustained, challenging macro-economic situation in the country. The one-off cost of closure amounts to preliminary MSEK 22 and will be reflected in the Q4 2021 financial statements. The decision will take effect immediately. This information is of the type that Concentric AB is obliged to make public pursuant to

STENOCARE is the only supplier of medical cannabis oil under the Danish Pilot Programme

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Reference is made to today’s formal announcement, that STENOCARE has been approved by the Danish Medicines Agency to once again sell medical cannabis oil under the Danish Pilot Programme. This press release serves as an elaboration on the perspectives.Sole supplier once again: After a long period of relentless work and ongoing cooperation with the Danish Medical Agency, STENOCARE is now once again able to benefit from being a first mover and sole supplier of medical cannabis oil under the Danish Pilot Programme.

STENOCARE approved to supply Danish patients with medical cannabis oil products

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“STENOCARE”) hereby announces that it has received approval from The Danish Medicines Agency to sell a new medical cannabis oil product to Danish patients. With this, STENOCARE once again becomes the only supplier of medical cannabis oil products under the Danish Pilot Programme.STENOCARE is a supplier of prescription-based medical cannabis products for patients’ treatment. The company has experience delivering prescription-based products for patients in Denmark and Sweden, and now re-enters the

Cloudberry Clean Energy ASA | Cloudberry completes acquisition of 60% of the Captiva Group

Oslo, Norway, 7 January 2022: Reference is made to the stock exchange announcement of 17 November 2021, newsweb.oslobors.no/message/547064, announcing Cloudberry Clean Energy ASA’s ("Cloudberry" or the "Company") potential acquisition of 60% of the Captiva Group (as defined below) (the “Transaction”). The parties have today entered into the share purchase agreement and completed the Transaction.Building a leading Nordic IPP“The challenging situation in the European energy markets, has highlighted the need for companies able to identify, develop, build, and operate renewable power assets.

Ombori Grid Now Available in the Microsoft Azure Marketplace

Microsoft Azure customers worldwide now gain access to Ombori Grid to take advantage of the scalability, reliability, and agility of Azure to drive application development and shape business strategies.Stockholm, Sweden – January 6, 2022 – OmboriGrid AB (publ) today announced the availability of Ombori Grid in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. OmboriGrid customers can now take advantage of the productive and trusted Azure cloud platform, with streamlined deployment and management. Ombori Grid is a SaaS platform designed

Techstep ASA - Primary insider notification

Giraff AS, a company owned 100% by primary insider CEO Børge Astrup, has on 7 January 2022 purchased 288,289 shares in Techstep ASA at a price of NOK 4.0723 per share. After this transaction Børge Astrup controls 682,082 shares in Techstep ASA. Please see the attached forms for further information. For further information, please contact: Børge Astrup, CEO, Techstep ASA: +47 928 27 676Marius Drefvelin, CFO, Techstep ASA: +47 958 95 690 The information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian

DanCann Pharma A/S: EUROPEAN UNION INTELLECTUAL PROPERTY OFFICE CERTIFICATE OF REGISTRATION for product portfolio trademarks

COPENHAGEN, Denmark, 07 January 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company has received the approvals of its trademarks for the future product portfolio through the EUROPEAN UNION INTELLECTUAL PROPERTY OFFICE CERTIFICATE OF REGISTRATION.DanCann Pharma has thus obtained the following protected trademarks: · TETRACANOID® (No 018533183) · BIDIOCANOID® (No 018533188) · MIXCANOID® (No 018533189) · VARINCANOID® (No 018533193) · BIGEROLCANOID® (No 018533195) The

There are no items matching the current filter
There are no more items matching the current filter
Back to top